Clinical Trial: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Study Status: Completed
Recruit Status: RECRUITING
Condition: Psoriatic Arthritis
Study Type: INTERVENTIONAL
Official Title: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)
Brief Summary:
The trial is a double-blinded randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Read more